Clinical trials: sponsored by Hoffmann-La Roche
Malignant Melanoma
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
This study will investigate the efficacy and safety of bevacizumab + fotemustine in patients with stage IV melanoma, previously untreated with chemo- or immunotherapy for metastatic disease.
- Trial name
- NCT01069627
- Testing
- bevacizumab [Avastin], fotemustine
- Where
- 4 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Healthy Participants
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
- Trial name
- NCT03596632
- Testing
- Fenebrutinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular…
- Trial name
- NCT01200758
- Testing
- Rituximab SC, Rituximab IV, Cyclophosphamide
- Where
- 152 sites in Australia, Belgium and 28 more
- Volunteers
- 410 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
This is an open-label Phase I study of single-agent trastuzumab emtansine administered by intravenous (IV) infusion. The study will characterize the pharmacokinetics of trastuzumab emtansine and its relevant analytes and the…
- Trial name
- NCT03153163
- Testing
- Trastuzumab Emtansine
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Study MO39939 is an open-label, single-arm, multicenter trial in patients with unresectable, locally-advanced or metastatic, clear or non-clear cell renal cell carcinoma (RCC) who have not received prior systemic therapy (who are…
- Trial name
- NCT03693573
- Testing
- Atezolizumab, Bevacizumab
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Lung Cancer, Cancer
Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
The purpose of this observational study is to describe patient and disease characteristics as well as treatment patterns in Chinese patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT02458651
- Testing
- No intervention
- Where
- 11 sites in China
- Volunteers
- 1,378 people
- Sponsor
- Hoffmann-La Roche
Non-Small-Cell Lung Carcinoma
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment.
- Trial name
- NCT01801111
- Testing
- Erlotinib, Alectinib
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of tocilizumab as a monotherapy or in combination with methotrexate or other conventional synthetic disease modifying antirheumatic…
- Trial name
- TOSCA (NCT02001987)
- Testing
- Tocilizumab, Methotrexate, csDMARDs
- Where
- 32 sites in France
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)…
- Trial name
- NCT01260181
- Testing
- Erlotinib
- Where
- 9 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
- Trial name
- NCT01429792
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 26 sites in Israel
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC.
- Trial name
- NCT02913443
- Testing
- RO7051790
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.
- Trial name
- NCT02616328
- Testing
- No intervention
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Influenza
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed…
- Trial name
- NCT01715909
- Testing
- Oseltamivir
- Where
- 50 sites in United States, Belgium and 13 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of vanucizumab as a single agent or in combination with atezolizumab in participants with locally advanced…
- Trial name
- NCT01688206
- Testing
- Atezolizumab [TECENTRIQ], Vanucizumab
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.
- Trial name
- NCT01178086
- Testing
- Rituximab
- Where
- Germany
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Beta-Thalassemia
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
This proof-of-mechanism study is being performed to investigate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of multiple oral doses of bitopertin in adults with NTD beta-thalassemia.
- Trial name
- NCT03271541
- Testing
- Bitopertin
- Where
- 4 sites in Italy, Lebanon and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants
This is a randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of Risdiplam in healthy Japanese participants.
- Trial name
- NCT03040635
- Testing
- Risdiplam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Spinal Muscular Atrophy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body.
- Trial name
- NCT02633709
- Testing
- Itraconazole, Risdiplam
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants
This is an open-label, non-randomized study investigating the excretion balance, PK and metabolism of a single oral dose of [14C]-labeled Risdiplam (RO7034067) in healthy male participants.
- Trial name
- NCT03036501
- Testing
- [^14C]-Risdiplam
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.